Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.30 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31178751 | 0.80 | CA2 (0.38) | CA2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL28474390 | 0.72 | CA2 (0.37) | CA2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL275290 | 0.72 | — | — | |
| SCHEMBL444566 | 0.71 | CA2 (0.44) | CA2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL27868365 | 0.70 | CA2 (0.42) | CA2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL13160703 | 0.70 | CA2 (0.35) | CA2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL4454952 | 0.67 | F2 (0.46) | CA2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL27991564 | 0.66 | CA2 (0.48) | CA2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7057430 | 0.65 | CA2 (0.34) | CA2CA1 | |
| SCHEMBL3144765 | 0.63 | CA2 (0.40) | CA2F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3091006-B1 | SULFONYLATION PROCESS USING NONAFLUOROBUTANESULFONYL FLUORIDE | JANSSEN PHARMACEUTICA NV (BE) | 2018-01-17 | — | — | EP | disclosed |
| EP-3091006-A1 | SULFONYLATION PROCESS USING NONAFLUOROBUTANESULFONYL FLUORIDE | Janssen Pharmaceutica N.V. (BE) | 2016-11-09 | — | — | EP | disclosed |
| EP-2882744-B1 | PROCESS FOR THE PREPARATION OF C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-21 | — | — | EP | disclosed |
| US-20150232439-A1 | PROCESS FOR THE PREPARATION OF C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-20 | — | — | US | disclosed |
| US-9029352-B2 | Process for the preparation of C-FMS kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-12 | — | — | US | disclosed |
| US-20140045789-A1 | PROCESS FOR THE PREPARATION OF C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232439-A1 | PROCESS FOR THE PREPARATION OF C-FMS KINASE INHIBITORS | FLT3, FES, FER | CA2 2395/4885F2 221/4885PRSS1 627/4885 |
| US-20140045789-A1 | PROCESS FOR THE PREPARATION OF C-FMS KINASE INHIBITORS | FLT3, FES, FER | CA2 2395/4885F2 221/4885PRSS1 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.